Hepatitis alcoholic – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:20:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hepatitis alcoholic – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of N-acetylcysteine and prednisolone combination versus extended prednisolone treatment in patients with severe alcoholic hepatitis https://clinicaltrials.eu/trial/study-of-n-acetylcysteine-and-prednisolone-combination-versus-extended-prednisolone-treatment-in-patients-with-severe-alcoholic-hepatitis/ Wed, 27 May 2026 04:04:54 +0000 https://clinicaltrials.eu/trial/study-of-n-acetylcysteine-and-prednisolone-combination-versus-extended-prednisolone-treatment-in-patients-with-severe-alcoholic-hepatitis/ This study focuses on treating alcoholic hepatitis, a severe liver condition caused by excessive alcohol consumption. The research evaluates different treatment approaches using two medications: prednisolone, a corticosteroid medication that helps reduce inflammation in the liver, and N-acetylcysteine, a substance that may help protect liver cells from damage.

The study compares three different treatment approaches: standard treatment with prednisolone for 30 days, extended prednisolone treatment for 60 days, or a combination of standard prednisolone treatment with N-acetylcysteine given over 5 days. The purpose is to determine which treatment method is most effective in helping patients recover from severe alcoholic hepatitis and maintain stable liver function after 90 days.

During the study, participants will receive either prednisolone tablets taken by mouth, N-acetylcysteine given through an intravenous line (directly into a vein), or placebo, depending on their assigned treatment group. Some patients will receive additional supportive treatments including dextrose and saline solutions. The study will monitor patients’ liver function and overall health throughout the treatment period and follow-up visits.

]]> Study on the Effectiveness of N-Acetylcysteine and Methylprednisolone for Patients with Severe Acute Alcoholic Hepatitis https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-n-acetylcysteine-and-methylprednisolone-for-patients-with-severe-acute-alcoholic-hepatitis/ Wed, 29 Apr 2026 15:03:55 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-n-acetylcysteine-and-methylprednisolone-for-patients-with-severe-acute-alcoholic-hepatitis/ This clinical trial is focused on studying the treatment of Severe Acute Alcoholic Hepatitis, a serious liver condition caused by excessive alcohol consumption. The study will use a combination of two medications: methylprednisolone, a type of steroid that helps reduce inflammation, and N-acetylcysteine (NAC), which is often used to help protect the liver. The purpose of the study is to evaluate how effective this combination is in reducing the risk of death within one month for patients suffering from this condition.

Participants in the study will receive the treatment through intravenous perfusion, which means the medication will be administered directly into the bloodstream. The study will monitor the patients over a period of time to assess not only the one-month mortality rate but also the mortality rates at three and six months. Additionally, the study will look at other factors such as liver complications, infections, kidney problems, and how well patients tolerate the NAC treatment.

The study will also explore the relationship between the Lille index, a score used to predict the outcome of treatment in patients with severe alcoholic hepatitis, and the response to the treatment after seven days. This research aims to provide valuable insights into the potential benefits of using methylprednisolone and NAC together for treating severe cases of alcoholic hepatitis.

]]> Study on the Effects of Alpha-1 Antitrypsin and Prednisolone in Patients with Severe Alcohol-Related Hepatitis https://clinicaltrials.eu/trial/study-on-the-effects-of-alpha-1-antitrypsin-and-prednisolone-in-patients-with-severe-alcohol-related-hepatitis/ Wed, 29 Apr 2026 15:03:49 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-alpha-1-antitrypsin-and-prednisolone-in-patients-with-severe-alcohol-related-hepatitis/ This clinical trial is focused on studying the effects of a treatment for Alcohol-Associated Hepatitis, a liver condition caused by excessive alcohol consumption. The study will use a medication called Alpha-1 Antitrypsin, which is a protein that helps reduce inflammation in the body. The treatment involves administering this protein through an intravenous infusion, which means it is given directly into the bloodstream through a vein.

The purpose of the study is to evaluate how effective Alpha-1 Antitrypsin is in reducing inflammation in patients with severe forms of this liver condition. Participants in the study will receive the treatment once a week for four weeks. Some participants will receive a placebo instead of the active treatment. The study will monitor the effects of the treatment over a period of time to see if it helps improve the condition of the liver and overall health of the participants.

Throughout the study, participants will have regular check-ups to assess their health and any changes in their condition. The study aims to gather information on the safety and effectiveness of Alpha-1 Antitrypsin as a potential treatment for Alcohol-Associated Hepatitis. This research could provide valuable insights into new ways to manage and treat this liver disease.

]]> Study on the Effects of INT-787 for Patients with Severe Alcohol-Associated Hepatitis https://clinicaltrials.eu/trial/study-on-the-effects-of-int-787-for-patients-with-severe-alcohol-associated-hepatitis/ Wed, 29 Apr 2026 14:29:09 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-int-787-for-patients-with-severe-alcohol-associated-hepatitis/ This clinical trial is focused on studying Severe Alcohol-Associated Hepatitis, a serious liver condition caused by excessive alcohol consumption. The study is testing a new treatment called INT-787, which is taken in the form of a capsule. The purpose of the study is to evaluate how effective INT-787 is in managing the progression of this liver disease.

Participants in the study will be randomly assigned to receive either the INT-787 treatment or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The treatment period will last for up to 28 days, during which the safety and tolerability of INT-787 will also be assessed.

The study aims to gather information on how INT-787 affects the liver condition over time, with a particular focus on its safety and how well it is tolerated by participants. The results will help determine if INT-787 could be a potential treatment option for people suffering from Severe Alcohol-Associated Hepatitis.

]]> Study on the Safety and Effects of Resatorvid and Filgrastim for Patients with Severe Alcoholic Hepatitis and Acute-on-Chronic Liver Failure https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-resatorvid-and-filgrastim-for-patients-with-severe-alcoholic-hepatitis-and-acute-on-chronic-liver-failure/ Wed, 29 Apr 2026 14:24:40 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-resatorvid-and-filgrastim-for-patients-with-severe-alcoholic-hepatitis-and-acute-on-chronic-liver-failure/ This clinical trial is focused on studying two serious liver conditions: severe alcoholic hepatitis (sAH) and acute-on-chronic liver failure (ACLF). Severe alcoholic hepatitis is a condition caused by excessive alcohol consumption, leading to liver inflammation. Acute-on-chronic liver failure is a syndrome that occurs in patients with chronic liver disease, characterized by sudden liver failure and potentially affecting other organs like the kidneys and brain. The study will test the safety of a new treatment combining two medications: Resatorvid (TAK-242), which is a selective inhibitor of TLR4-mediated signaling, and Granulocyte Colony-Stimulating Factor (G-CSF), a substance that helps the body produce more white blood cells. A placebo will also be used for comparison.

The purpose of this study is to evaluate the safety of the combination treatment in patients with these liver conditions. Participants will receive either the combination of Resatorvid and G-CSF, Resatorvid alone, or a placebo. The treatment will be administered over a period of up to 10 days. The study will monitor the participants for any side effects and assess the impact of the treatment on liver function and overall health. The trial aims to understand how the treatment affects inflammation, liver function, and the body’s ability to recover from liver failure.

Throughout the study, researchers will collect data on various health markers, including inflammation and liver function, to determine the effectiveness of the treatment. The study will also look at the quality of life of participants and the number of days they spend in intensive care. The ultimate goal is to find a safe and effective treatment option for patients suffering from severe alcoholic hepatitis and acute-on-chronic liver failure.

]]>